- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06376968
Prospektive, multizentrische, randomisierte, kontrollierte Cross-Over-Studie zur Sicherheit und Leistung der biologischen Fusionsoption von DialogiQ im Vergleich zur Hämodialyse ohne biologische Fusion bei zu Hypotonie neigenden Patienten unter Erhaltungshämodialyse
The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:
• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.
A crossover design is used to compare treatments with or without the BioLogic Fusion function activated.
Studienübersicht
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Strube Frank
- Telefonnummer: +4915257240618
- E-Mail: frank.strube@bbraun.com
Studieren Sie die Kontaktsicherung
- Name: Seebode Christina, Dr.
- E-Mail: christina.seebode@bbraun.com
Studienorte
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italien, 40138
- Rekrutierung
- Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione
-
Kontakt:
- Annalisa Zucchelli, Prof.
-
Hauptermittler:
- Annalisa Zucchelli, Prof.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female subjects ≥18 years of age
- Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months
- Dialysis frequency 3 x per week
- Dialysis duration per session ≥ 4h
- Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes
- No residual renal function (definition: ≤100 ml urine/day) - changed to "No to minimal residual renal function (definition: ≤ 300 ml/day)" with Amendment 1 (CIP version 6)
- Stable dry body weight for at least 4 weeks
- Subjects who are willing to give a voluntary consent to participate in the study
Exclusion Criteria:
- Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
- Vascular access insufficiency (mean blood flow <200ml/min)
- Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: " Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles" with Amendment 1 (CIP version 6)
- Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)
- Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period
- Factors which may interfere with full participation in the trial
- Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)
- Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: BioLogic Fusion followed by standard dialysis
Patients will be dialysed first with the BioLogic Fusion feature activated and then switched to standard dialysis with the BioLogic Fusion feature de-activated |
Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes. Intervention duration in total 28 weeks - 12 weeks standard treatment, 4 weeks learning phase BioLogic Fusion, 12 weeks BioLogic Fusion |
|
Experimental: Standard dialysis followed by BioLogic Fusion
Patients will be dialysed first with standard dialysis with the BioLogic Fusion feature de-activated and then switched to the BioLogic Fusion feature activated |
Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes. Intervention duration in total 28 weeks - 12 weeks standard treatment, 4 weeks learning phase BioLogic Fusion, 12 weeks BioLogic Fusion |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Post-dialysis body weight
Zeitfenster: 12 weeks
|
percentage of sessions with reached prescribed post-dialysis body weight |
12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Annalisa Zucchelli, MD, University Hospital Bologna
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- BA-G-H-1604
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .